microRNA information: hsa-miR-342-5p
| Section | ID | link |
|---|---|---|
| Mature name: | hsa-miR-342-5p | miRbase |
| Accession: | MIMAT0004694 | miRbase |
| Precursor name: | hsa-mir-342 | miRbase |
| Precursor accession: | MI0000805 | miRbase |
| Symbol: | MIR342 | HGNC |
| RefSeq ID: | NR_029888 | GenBank |
| Sequence: | AGGGGUGCUAUCUGUGAUUGA |
Reported expression in cancers: hsa-miR-342-5p
| miRNA | cancer | regulation | reporting | PUBMED | method |
|---|---|---|---|---|---|
| hsa-miR-342-5p | acute myeloid leukemia | deregulation | "Circulating miR 150 and miR 342 in plasma are nove ......" | 23391324 | Microarray; qPCR |
| hsa-miR-342-5p | breast cancer | downregulation | "Increased expression of three of the most promisin ......" | 18708351 | Reverse transcription PCR; qPCR |
| hsa-miR-342-5p | breast cancer | downregulation | "Stepwise ANN analysis identified predictive miRNA ......" | 19432961 | |
| hsa-miR-342-5p | breast cancer | downregulation | "Downregulation of miR 342 is associated with tamox ......" | 21172025 | |
| hsa-miR-342-5p | breast cancer | downregulation | "We demonstrated the clinical relevance of the miRN ......" | 24148764 | |
| hsa-miR-342-5p | colorectal cancer | deregulation | "MicroRNA 342 inhibits colorectal cancer cell proli ......" | 21565830 | |
| hsa-miR-342-5p | gastric cancer | upregulation | "miRNA expression was determined using a custom-des ......" | 22112324 | Microarray |
| hsa-miR-342-5p | lung cancer | deregulation | "The expression of 319 miRNAs was evaluated by Exiq ......" | 20818338 | Microarray |
| hsa-miR-342-5p | sarcoma | downregulation | "Similar analysis in mouse metastatic sarcomas reve ......" | 26044957 |
Reported cancer pathway affected by hsa-miR-342-5p
| miRNA | cancer | pathway | reporting | PUBMED | functional study |
|---|---|---|---|---|---|
| hsa-miR-342-5p | breast cancer | Apoptosis pathway; cell cycle pathway | "Downregulation of miR 342 is associated with tamox ......" | 21172025 | |
| hsa-miR-342-5p | breast cancer | Apoptosis pathway | "miR 342 is associated with estrogen receptor α ex ......" | 23408138 | |
| hsa-miR-342-5p | breast cancer | Apoptosis pathway | "Effect of miR 342 3p on chemotherapy sensitivity i ......" | 24921394 | Flow cytometry |
| hsa-miR-342-5p | breast cancer | Apoptosis pathway | "miR 342 overexpression results in a synthetic leth ......" | 26919240 | Luciferase |
| hsa-miR-342-5p | colon cancer | cell cycle pathway; Apoptosis pathway | "microRNA 342 5p and miR 608 inhibit colon cancer t ......" | 26646451 | |
| hsa-miR-342-5p | colorectal cancer | Apoptosis pathway | "Epigenetic silencing of the intronic microRNA hsa ......" | 18264139 | |
| hsa-miR-342-5p | gastric cancer | Apoptosis pathway | "In order to identify miRNA signatures for gastric ......" | 22112324 |
Reported cancer prognosis affected by hsa-miR-342-5p
| miRNA | cancer | prognosis | reporting | PUBMED | functional study |
|---|---|---|---|---|---|
| hsa-miR-342-5p | breast cancer | worse prognosis | "Stepwise ANN analysis identified predictive miRNA ......" | 19432961 | |
| hsa-miR-342-5p | breast cancer | drug resistance; progression | "Downregulation of miR 342 is associated with tamox ......" | 21172025 | |
| hsa-miR-342-5p | breast cancer | drug resistance | "miR 342 is associated with estrogen receptor α ex ......" | 23408138 | |
| hsa-miR-342-5p | breast cancer | poor survival | "Rank product analyses identified 38 miRNAs q < 0 ......" | 24148764 | |
| hsa-miR-342-5p | breast cancer | recurrence | "Using microarray-based technology we have performe ......" | 24632820 | |
| hsa-miR-342-5p | breast cancer | drug resistance | "The few available studies investigating microRNA i ......" | 26473850 | |
| hsa-miR-342-5p | cervical and endocervical cancer | drug resistance | "Seven differentially expressed miRNAs were selecte ......" | 27423381 | |
| hsa-miR-342-5p | colon cancer | tumorigenesis; progression | "microRNA 342 5p and miR 608 inhibit colon cancer t ......" | 26646451 | |
| hsa-miR-342-5p | colorectal cancer | metastasis | "MicroRNA 342 inhibits colorectal cancer cell proli ......" | 21565830 | |
| hsa-miR-342-5p | gastric cancer | drug resistance | "In order to identify miRNA signatures for gastric ......" | 22112324 |
Reported gene related to hsa-miR-342-5p
| miRNA | cancer | gene | reporting | PUBMED |
|---|---|---|---|---|
| hsa-miR-342-5p | bladder cancer | FOXM1 | "Long non coding RNA H19 regulates FOXM1 expression ......" | 27716361 |
| hsa-miR-342-5p | cervical and endocervical cancer | FOXM1 | "miR 342 3p suppresses proliferation migration and ......" | 25066298 |
| hsa-miR-342-5p | colorectal cancer | FOXM1 | "FOXM1 and FOXQ1 Are Promising Prognostic Biomarker ......" | 27162244 |
| hsa-miR-342-5p | breast cancer | BRCA1 | "miR 342 overexpression results in a synthetic leth ......" | 26919240 |
| hsa-miR-342-5p | breast cancer | BRCA1 | "miR 342 regulates BRCA1 expression through modulat ......" | 24475217 |
| hsa-miR-342-5p | breast cancer | ERBB2 | "Statistically significant associations were observ ......" | 23408138 |
| hsa-miR-342-5p | breast cancer | ERBB2 | "We observed significant and dramatic downregulatio ......" | 21172025 |
| hsa-miR-342-5p | breast cancer | ESR1 | "miR 342 is associated with estrogen receptor α ex ......" | 23408138 |
| hsa-miR-342-5p | breast cancer | ESR1 | "Expression of miR-342 has been strongly correlated ......" | 26919240 |
| hsa-miR-342-5p | breast cancer | BIRC6 | "Using an in silico approach and a luciferase repor ......" | 26919240 |
| hsa-miR-342-5p | colorectal cancer | DNMT1 | "Restoration of miR-342 resulted in a dramatic redu ......" | 21565830 |
| hsa-miR-342-5p | lung cancer | E2F1 | "miR 342 3p regulates MYC transcriptional activity ......" | 26483346 |
| hsa-miR-342-5p | colorectal cancer | EVL | "Epigenetic silencing of the intronic microRNA hsa ......" | 18264139 |
| hsa-miR-342-5p | lung squamous cell cancer | FGFR3 | "Further studies revealed that the growth of SCLC c ......" | 27670444 |
| hsa-miR-342-5p | colorectal cancer | FOXQ1 | "FOXM1 and FOXQ1 Are Promising Prognostic Biomarker ......" | 27162244 |
| hsa-miR-342-5p | bladder cancer | H19 | "Long non coding RNA H19 regulates FOXM1 expression ......" | 27716361 |
| hsa-miR-342-5p | breast cancer | ID4 | "miR 342 regulates BRCA1 expression through modulat ......" | 24475217 |
| hsa-miR-342-5p | lung cancer | MYC | "miR 342 3p regulates MYC transcriptional activity ......" | 26483346 |
| hsa-miR-342-5p | colon cancer | NAA10 | "microRNA 342 5p and miR 608 inhibit colon cancer t ......" | 26646451 |
| hsa-miR-342-5p | liver cancer | NFASC | "miR 342 3p affects hepatocellular carcinoma cell p ......" | 25580008 |
| hsa-miR-342-5p | lung squamous cell cancer | PTPRN | "Small cell lung cancer growth is inhibited by miR ......" | 27670444 |
| hsa-miR-342-5p | lung squamous cell cancer | RAP2B | "miR 342 3p targets RAP2B to suppress proliferation ......" | 25663460 |
| hsa-miR-342-5p | lung squamous cell cancer | SCLC1 | "The present experiments were initiated to see whet ......" | 27670444 |
| hsa-miR-342-5p | lymphoma | TIAM1 | "Expression of microRNA 10a microRNA 342 3p and the ......" | 26870215 |
| hsa-miR-342-5p | breast cancer | VEGFA | "Statistically significant associations were observ ......" | 23408138 |
Expression profile in cancer corhorts:
Putative target regulations
| miRNA | Gene | Cancer | Interaction | Correlation beta |
|---|---|---|---|---|
hsa-miR-342-5p | NFE2L1 | 10 cancers: BLCA; CESC; HNSC; KIRC; LIHC; LUSC; PRAD; SARC; THCA; UCEC | miRNAWalker2 validate | TCGA BLCA -0.113; TCGA CESC -0.059; TCGA HNSC -0.112; TCGA KIRC -0.093; TCGA LIHC -0.184; TCGA LUSC -0.175; TCGA PRAD -0.065; TCGA SARC -0.112; TCGA THCA -0.151; TCGA UCEC -0.115 |
hsa-miR-342-5p | PTPRG | 10 cancers: BLCA; CESC; ESCA; HNSC; KIRC; KIRP; LUSC; PRAD; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.21; TCGA CESC -0.375; TCGA ESCA -0.267; TCGA HNSC -0.213; TCGA KIRC -0.139; TCGA KIRP -0.196; TCGA LUSC -0.173; TCGA PRAD -0.115; TCGA THCA -0.212; TCGA STAD -0.112 |
hsa-miR-342-5p | LMNA | 10 cancers: BLCA; BRCA; ESCA; HNSC; LIHC; LUSC; PAAD; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.069; TCGA BRCA -0.204; TCGA ESCA -0.13; TCGA HNSC -0.084; TCGA LIHC -0.11; TCGA LUSC -0.183; TCGA PAAD -0.284; TCGA PRAD -0.083; TCGA STAD -0.072; TCGA UCEC -0.231 |
hsa-miR-342-5p | TMEM231 | 9 cancers: BLCA; CESC; KIRC; KIRP; LGG; OV; PRAD; THCA; STAD | MirTarget | TCGA BLCA -0.09; TCGA CESC -0.193; TCGA KIRC -0.145; TCGA KIRP -0.098; TCGA LGG -0.088; TCGA OV -0.157; TCGA PRAD -0.076; TCGA THCA -0.208; TCGA STAD -0.173 |
hsa-miR-342-5p | CSDC2 | 9 cancers: BLCA; BRCA; HNSC; KIRC; LGG; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.62; TCGA BRCA -0.264; TCGA HNSC -0.484; TCGA KIRC -0.604; TCGA LGG -0.469; TCGA PRAD -0.217; TCGA SARC -0.465; TCGA STAD -0.145; TCGA UCEC -0.38 |
hsa-miR-342-5p | SORBS2 | 10 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LIHC; LUAD; PRAD; SARC; STAD | MirTarget | TCGA BLCA -0.517; TCGA BRCA -0.157; TCGA CESC -0.542; TCGA ESCA -0.316; TCGA HNSC -0.198; TCGA LIHC -0.22; TCGA LUAD -0.179; TCGA PRAD -0.18; TCGA SARC -0.404; TCGA STAD -0.441 |
hsa-miR-342-5p | MKL2 | 9 cancers: BLCA; CESC; HNSC; KIRC; LIHC; LUAD; THCA; STAD; UCEC | MirTarget; PITA; miRNATAP | TCGA BLCA -0.103; TCGA CESC -0.069; TCGA HNSC -0.11; TCGA KIRC -0.057; TCGA LIHC -0.072; TCGA LUAD -0.11; TCGA THCA -0.072; TCGA STAD -0.09; TCGA UCEC -0.115 |
hsa-miR-342-5p | ZBTB47 | 11 cancers: BLCA; BRCA; CESC; ESCA; KIRC; LGG; PRAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.199; TCGA BRCA -0.129; TCGA CESC -0.079; TCGA ESCA -0.234; TCGA KIRC -0.182; TCGA LGG -0.249; TCGA PRAD -0.075; TCGA SARC -0.251; TCGA THCA -0.173; TCGA STAD -0.205; TCGA UCEC -0.164 |
hsa-miR-342-5p | MPL | 12 cancers: BLCA; BRCA; CESC; ESCA; KIRC; LIHC; LUAD; PRAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.249; TCGA BRCA -0.126; TCGA CESC -0.102; TCGA ESCA -0.182; TCGA KIRC -0.197; TCGA LIHC -0.107; TCGA LUAD -0.08; TCGA PRAD -0.16; TCGA SARC -0.58; TCGA THCA -0.096; TCGA STAD -0.314; TCGA UCEC -0.133 |
hsa-miR-342-5p | PPARGC1A | 9 cancers: BLCA; BRCA; HNSC; KIRC; KIRP; PAAD; PRAD; SARC; STAD | MirTarget; PITA; miRNATAP | TCGA BLCA -0.738; TCGA BRCA -0.43; TCGA HNSC -0.366; TCGA KIRC -0.863; TCGA KIRP -0.332; TCGA PAAD -0.524; TCGA PRAD -0.533; TCGA SARC -0.871; TCGA STAD -0.518 |
hsa-miR-342-5p | ENAH | 12 cancers: BLCA; CESC; COAD; HNSC; LGG; LUAD; LUSC; PRAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.164; TCGA CESC -0.123; TCGA COAD -0.139; TCGA HNSC -0.145; TCGA LGG -0.196; TCGA LUAD -0.145; TCGA LUSC -0.257; TCGA PRAD -0.077; TCGA SARC -0.324; TCGA THCA -0.144; TCGA STAD -0.273; TCGA UCEC -0.134 |
hsa-miR-342-5p | UBE3B | 9 cancers: BLCA; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; SARC; THCA | MirTarget | TCGA BLCA -0.082; TCGA ESCA -0.066; TCGA HNSC -0.05; TCGA KIRC -0.095; TCGA KIRP -0.071; TCGA LIHC -0.061; TCGA LUAD -0.088; TCGA SARC -0.129; TCGA THCA -0.128 |
hsa-miR-342-5p | BMPR2 | 10 cancers: BLCA; CESC; HNSC; KIRP; LUAD; PRAD; SARC; THCA; STAD; UCEC | PITA | TCGA BLCA -0.196; TCGA CESC -0.077; TCGA HNSC -0.096; TCGA KIRP -0.112; TCGA LUAD -0.07; TCGA PRAD -0.089; TCGA SARC -0.08; TCGA THCA -0.088; TCGA STAD -0.093; TCGA UCEC -0.205 |
hsa-miR-342-5p | PCDH1 | 9 cancers: BLCA; CESC; ESCA; HNSC; KIRC; KIRP; PAAD; THCA; UCEC | PITA; miRNATAP | TCGA BLCA -0.127; TCGA CESC -0.206; TCGA ESCA -0.346; TCGA HNSC -0.18; TCGA KIRC -0.467; TCGA KIRP -0.475; TCGA PAAD -0.395; TCGA THCA -0.234; TCGA UCEC -0.201 |
hsa-miR-342-5p | DGCR2 | 9 cancers: BLCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; THCA | mirMAP | TCGA BLCA -0.057; TCGA HNSC -0.091; TCGA KIRP -0.064; TCGA LGG -0.218; TCGA LIHC -0.119; TCGA LUAD -0.054; TCGA LUSC -0.111; TCGA PAAD -0.107; TCGA THCA -0.062 |
hsa-miR-342-5p | MGLL | 10 cancers: BLCA; BRCA; CESC; ESCA; HNSC; PAAD; PRAD; SARC; STAD; UCEC | mirMAP | TCGA BLCA -0.137; TCGA BRCA -0.217; TCGA CESC -0.281; TCGA ESCA -0.217; TCGA HNSC -0.206; TCGA PAAD -0.234; TCGA PRAD -0.181; TCGA SARC -0.15; TCGA STAD -0.214; TCGA UCEC -0.135 |
hsa-miR-342-5p | GNA11 | 10 cancers: BLCA; CESC; ESCA; HNSC; KIRC; KIRP; LUSC; PRAD; SARC; THCA | mirMAP | TCGA BLCA -0.166; TCGA CESC -0.154; TCGA ESCA -0.214; TCGA HNSC -0.127; TCGA KIRC -0.338; TCGA KIRP -0.337; TCGA LUSC -0.122; TCGA PRAD -0.159; TCGA SARC -0.354; TCGA THCA -0.278 |
hsa-miR-342-5p | DAB2IP | 10 cancers: BLCA; BRCA; ESCA; KIRC; KIRP; OV; PRAD; SARC; THCA; UCEC | mirMAP | TCGA BLCA -0.107; TCGA BRCA -0.188; TCGA ESCA -0.152; TCGA KIRC -0.178; TCGA KIRP -0.139; TCGA OV -0.119; TCGA PRAD -0.141; TCGA SARC -0.137; TCGA THCA -0.083; TCGA UCEC -0.094 |
hsa-miR-342-5p | IGF1R | 11 cancers: BLCA; CESC; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; PRAD; SARC; THCA | mirMAP | TCGA BLCA -0.172; TCGA CESC -0.207; TCGA HNSC -0.202; TCGA KIRC -0.202; TCGA KIRP -0.166; TCGA LGG -0.113; TCGA LUAD -0.134; TCGA LUSC -0.295; TCGA PRAD -0.101; TCGA SARC -0.231; TCGA THCA -0.158 |
hsa-miR-342-5p | WASF2 | 9 cancers: BLCA; BRCA; HNSC; OV; PRAD; SARC; THCA; STAD; UCEC | mirMAP | TCGA BLCA -0.094; TCGA BRCA -0.068; TCGA HNSC -0.074; TCGA OV -0.166; TCGA PRAD -0.064; TCGA SARC -0.088; TCGA THCA -0.064; TCGA STAD -0.07; TCGA UCEC -0.099 |
hsa-miR-342-5p | TOM1L2 | 9 cancers: BLCA; HNSC; KIRC; KIRP; LIHC; SARC; THCA; STAD; UCEC | mirMAP | TCGA BLCA -0.106; TCGA HNSC -0.123; TCGA KIRC -0.355; TCGA KIRP -0.107; TCGA LIHC -0.075; TCGA SARC -0.338; TCGA THCA -0.093; TCGA STAD -0.147; TCGA UCEC -0.112 |
hsa-miR-342-5p | CBX6 | 9 cancers: BLCA; HNSC; KIRC; KIRP; PRAD; SARC; THCA; STAD; UCEC | mirMAP | TCGA BLCA -0.19; TCGA HNSC -0.123; TCGA KIRC -0.256; TCGA KIRP -0.14; TCGA PRAD -0.22; TCGA SARC -0.217; TCGA THCA -0.246; TCGA STAD -0.18; TCGA UCEC -0.204 |
hsa-miR-342-5p | DUSP8 | 10 cancers: BLCA; CESC; ESCA; HNSC; KIRC; PAAD; SARC; THCA; STAD; UCEC | mirMAP | TCGA BLCA -0.168; TCGA CESC -0.182; TCGA ESCA -0.204; TCGA HNSC -0.165; TCGA KIRC -0.399; TCGA PAAD -0.186; TCGA SARC -0.297; TCGA THCA -0.177; TCGA STAD -0.103; TCGA UCEC -0.149 |
hsa-miR-342-5p | C15orf52 | 11 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; LGG; PRAD; SARC; STAD; UCEC | mirMAP | TCGA BLCA -0.371; TCGA BRCA -0.247; TCGA CESC -0.359; TCGA ESCA -0.227; TCGA HNSC -0.192; TCGA KIRC -0.239; TCGA LGG -0.177; TCGA PRAD -0.076; TCGA SARC -0.657; TCGA STAD -0.495; TCGA UCEC -0.208 |
hsa-miR-342-5p | KIF13B | 10 cancers: BLCA; CESC; ESCA; KIRC; KIRP; LUAD; PAAD; SARC; THCA; UCEC | mirMAP | TCGA BLCA -0.186; TCGA CESC -0.161; TCGA ESCA -0.299; TCGA KIRC -0.485; TCGA KIRP -0.104; TCGA LUAD -0.095; TCGA PAAD -0.192; TCGA SARC -0.101; TCGA THCA -0.157; TCGA UCEC -0.143 |
hsa-miR-342-5p | FYCO1 | 9 cancers: BLCA; ESCA; HNSC; KIRC; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.336; TCGA ESCA -0.247; TCGA HNSC -0.124; TCGA KIRC -0.188; TCGA PRAD -0.144; TCGA SARC -0.308; TCGA THCA -0.111; TCGA STAD -0.237; TCGA UCEC -0.231 |
hsa-miR-342-5p | SLC2A4 | 9 cancers: BLCA; BRCA; KIRC; LGG; LIHC; PRAD; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -0.725; TCGA BRCA -0.444; TCGA KIRC -0.458; TCGA LGG -0.321; TCGA LIHC -0.221; TCGA PRAD -0.498; TCGA SARC -0.389; TCGA STAD -0.643; TCGA UCEC -0.273 |
hsa-miR-342-5p | TOB2 | 12 cancers: BLCA; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; OV; PAAD; STAD; UCEC | miRNATAP | TCGA BLCA -0.075; TCGA ESCA -0.159; TCGA HNSC -0.08; TCGA KIRC -0.156; TCGA KIRP -0.178; TCGA LGG -0.187; TCGA LIHC -0.132; TCGA LUAD -0.093; TCGA OV -0.079; TCGA PAAD -0.08; TCGA STAD -0.083; TCGA UCEC -0.105 |
hsa-miR-342-5p | PRKAR2A | 13 cancers: BLCA; CESC; ESCA; HNSC; KIRC; KIRP; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.245; TCGA CESC -0.27; TCGA ESCA -0.28; TCGA HNSC -0.225; TCGA KIRC -0.373; TCGA KIRP -0.275; TCGA LUAD -0.096; TCGA LUSC -0.116; TCGA OV -0.096; TCGA PRAD -0.169; TCGA SARC -0.2; TCGA THCA -0.327; TCGA STAD -0.121 |
hsa-miR-342-5p | UBE2W | 10 cancers: BLCA; COAD; HNSC; KIRC; KIRP; LUAD; OV; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.056; TCGA COAD -0.109; TCGA HNSC -0.085; TCGA KIRC -0.143; TCGA KIRP -0.087; TCGA LUAD -0.137; TCGA OV -0.085; TCGA THCA -0.094; TCGA STAD -0.092; TCGA UCEC -0.11 |
hsa-miR-342-5p | ILK | 9 cancers: BLCA; CESC; ESCA; LGG; PAAD; PRAD; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -0.195; TCGA CESC -0.088; TCGA ESCA -0.123; TCGA LGG -0.078; TCGA PAAD -0.087; TCGA PRAD -0.181; TCGA SARC -0.361; TCGA STAD -0.163; TCGA UCEC -0.134 |
hsa-miR-342-5p | MYH11 | 9 cancers: BLCA; BRCA; CESC; HNSC; KIRC; PRAD; SARC; STAD; UCEC | miRNATAP | TCGA BLCA -1.11; TCGA BRCA -0.356; TCGA CESC -0.464; TCGA HNSC -0.633; TCGA KIRC -0.18; TCGA PRAD -0.573; TCGA SARC -1.878; TCGA STAD -0.759; TCGA UCEC -0.757 |
hsa-miR-342-5p | EIF3D | 9 cancers: BRCA; HNSC; LGG; LIHC; LUAD; LUSC; OV; PAAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.062; TCGA HNSC -0.052; TCGA LGG -0.193; TCGA LIHC -0.077; TCGA LUAD -0.062; TCGA LUSC -0.135; TCGA OV -0.122; TCGA PAAD -0.084; TCGA UCEC -0.056 |
hsa-miR-342-5p | RASL10B | 10 cancers: BRCA; CESC; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; PRAD; STAD | MirTarget | TCGA BRCA -0.284; TCGA CESC -0.322; TCGA HNSC -0.277; TCGA KIRC -0.267; TCGA KIRP -0.239; TCGA LGG -0.096; TCGA LIHC -0.664; TCGA LUSC -0.256; TCGA PRAD -0.118; TCGA STAD -0.199 |
hsa-miR-342-5p | DDX1 | 12 cancers: CESC; COAD; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; OV; PAAD; THCA; UCEC | miRNAWalker2 validate | TCGA CESC -0.079; TCGA COAD -0.051; TCGA HNSC -0.05; TCGA KIRC -0.102; TCGA KIRP -0.102; TCGA LIHC -0.097; TCGA LUAD -0.11; TCGA LUSC -0.149; TCGA OV -0.083; TCGA PAAD -0.089; TCGA THCA -0.084; TCGA UCEC -0.077 |
hsa-miR-342-5p | ACVR2B | 10 cancers: CESC; COAD; KIRC; KIRP; LGG; LUAD; LUSC; OV; THCA; STAD | miRNATAP | TCGA CESC -0.18; TCGA COAD -0.075; TCGA KIRC -0.233; TCGA KIRP -0.135; TCGA LGG -0.212; TCGA LUAD -0.081; TCGA LUSC -0.129; TCGA OV -0.125; TCGA THCA -0.068; TCGA STAD -0.117 |
hsa-miR-342-5p | NARS2 | 12 cancers: CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; THCA | miRNATAP | TCGA CESC -0.158; TCGA COAD -0.107; TCGA ESCA -0.09; TCGA HNSC -0.113; TCGA KIRC -0.174; TCGA KIRP -0.092; TCGA LGG -0.11; TCGA LIHC -0.071; TCGA LUAD -0.097; TCGA LUSC -0.112; TCGA OV -0.122; TCGA THCA -0.129 |
hsa-miR-342-5p | OXSR1 | 11 cancers: CESC; ESCA; KIRC; KIRP; LUAD; LUSC; OV; SARC; THCA; STAD; UCEC | miRNATAP | TCGA CESC -0.072; TCGA ESCA -0.131; TCGA KIRC -0.146; TCGA KIRP -0.089; TCGA LUAD -0.054; TCGA LUSC -0.109; TCGA OV -0.103; TCGA SARC -0.063; TCGA THCA -0.074; TCGA STAD -0.069; TCGA UCEC -0.074 |
hsa-miR-342-5p | IRF6 | 11 cancers: COAD; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; PAAD; PRAD; SARC; THCA | MirTarget | TCGA COAD -0.066; TCGA HNSC -0.117; TCGA KIRC -1.018; TCGA KIRP -0.341; TCGA LIHC -0.287; TCGA LUAD -0.138; TCGA LUSC -0.341; TCGA PAAD -0.411; TCGA PRAD -0.11; TCGA SARC -0.891; TCGA THCA -0.16 |
Enriched cancer pathways of putative targets